A 52-year-old Japanese male with moderate to severe plaque psoriasis has been treated with deucravacitinib 6 mg once daily for 18 months. His medical history includes well-controlled hypertension and no prior history of infections or malignancies. He presents for routine follow-up, and you are asked to counsel him on safety monitoring and potential adverse effects during long-term therapy.

Which of the following adverse events should the pharmacist emphasize as having a low but notable incidence during long-term deucravacitinib therapy based on 3-year Japanese patient data?

A 45-year-old Japanese female with moderate to severe plaque psoriasis started deucravacitinib 6 mg once daily 3 years ago. She achieved a PASI 75 response at 1 year and continues therapy. She asks about the likelihood of maintaining her clinical response long-term.

Based on the 3-year data from the POETYK PSO-1 and PSO-4 trials, what is the most accurate statement regarding the durability of deucravacitinib’s efficacy in Japanese patients?

A 60-year-old Japanese male with moderate to severe plaque psoriasis and a history of controlled cardiovascular disease is considering starting oral therapy. He is concerned about safety and efficacy over several years. He has no history of malignancy or thromboembolic events and is currently on antihypertensive therapy.

Considering the 3-year safety and efficacy data of deucravacitinib in Japanese patients, what is the most appropriate pharmacist recommendation regarding its use in this patient?